MedPath
FDA Approval

LAMIVUDINE and ZIDOVUDINE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
January 14, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Lamivudine(150 mg in 1 1)
Zidovudine(300 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

NuCare Pharmaceuticals,Inc.

NuCare Pharmaceuticals,Inc.

010632300

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LAMIVUDINE and ZIDOVUDINE

Product Details

NDC Product Code
68071-4450
Application Number
ANDA079124
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
January 14, 2022
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
HYPROMELLOSESInactive
Code: 3NXW29V3WOClass: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1AClass: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT
Code: 2T8Q726O95Class: ACTIBQuantity: 150 mg in 1 1
Code: 4B9XT59T7SClass: ACTIBQuantity: 300 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath